

UTILITY PATENT APPLICATION TRANSMITTAL



(only for new non-provisional applications under 37 CFR §1.53(b))

012004

Mail Stop Patent Application
 Commissioner for Patents
 P. O. Box 1450
 Alexandria, VA 22313-1450

I hereby certify that this correspondence is being
 deposited with the United States Postal Service as
 Express Mail in an envelope addressed to Mail Stop
 Patent Application, Commissioner for Patents, P.O.
 Box 1450, Alexandria, VA 22313-1450, on

1-20-04

Date of Deposit

Signature

EL964822278US

Express Mail No.

Transmitted herewith for filing is the patent application
 under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: USHMR2037 US DIV 1

INVENTORS: Ronald C. Bernotas, et al

TITLE: A METHOD FOR THE ISOLATION OF
 SULFURIC ACID MONO-[3-({1-[2-(4-
 FLUOROPHENYL)-ETHYL]-PIPERIDIN-4-
 YL}-HYDROXY-METHYL)-2-METHOXY-
 PHENYL]ESTER

APPLICATION ELEMENTS

1. *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)

2. Specification Total Pages 35

(preferred arrangement set forth below)

- Descriptive title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (*if filed*)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

3. Drawing(s) (35 U.S.C. 113) Total Sheets

4. Oath or Declaration Total Pages 8

a. Newly executed (original or copy)

b. Copy from a prior application (37 CFR § 1.63(d))

i. DELETION OF INVENTOR(S)

Signed statement attached deleting inventor(s) named in the prior
 application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).

5. Power of Attorney Total Pages

a. Newly executed (original or copy)

b. Copy from a prior application (37 CFR § 1.63(d))

6. Microfiche Computer Program (*Appendix*)

31355 U.S. PTO
 10/760515



7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

- Computer Readable Copy
- Paper Copy (identical to computer copy)
- Statement verifying identity of above copies

If a **CONTINUING Application**, check appropriate box, and supply the requisite information:

Continuation Divisional Continuation-in-part

of prior application no: 10/200,821, filed July 22, 2002, now allowed,

which is a division of 09/615,246, filed July 13, 2000, now U.S. Patent No. 6,465,490

B1, issued, October 15, 2002.

Examiner _____, Group/Art Unit _____.

(The cross reference has been/will be inserted on page one of the specification).

This application claims the benefit of U.S. Provisional Application No. 60/198,215, filed July 16, 1999. (The cross reference has been/will be inserted on page one of the specification).

Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)

The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ACCOMPANYING APPLICATION PARTS

7. Assignment Papers (*cover sheet & document(s)*)
8. 37 CFR §3.73(b) Statement
(*when there is an assignee*)
9. Verified English Translation Document (*if applicable*)
10. Information Disclosure Copies of IDS Citations
Statement (IDS)/PTO-1449
11. Preliminary Amendment
12. Return Receipt Postcard (MPEP 503)
(*Should be specifically itemized*)
13. *Small Entity Statement(s) Statement filed in prior application,
(PTO/SB/09-12) Status still proper and desired
14. Certified Copy of Priority Document(s)
(*if foreign priority is claimed*)
15. Other: Application Data Sheet (4 pgs)

CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label

005487

(Insert Customer No. or Attach bar code label here)

Balaran Gupta

Balaran Gupta, Reg. No. 40,009
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3364
Telefax (908) 231-2626
Aventis Docket No. HMR2037 US DIV 1

FEE TRANSMITTAL

for FY 2004

Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT

(\$ 770.00)

Complete if Known

Application Number	N T Y t Assigned
Filing Date	Concurr ntly Filed Herewith
First Named Inventor	R nald C. B rn tas, t al
Examiner Name	

Group / Art Unit

Attorney Docket No.

HMR2037 US DIV 1

METHOD OF PAYMENT (check all that apply)

 Check Credit Card Money Order Other None
 Deposit AccountDeposit Account Number
18-1982Deposit Account Name
Aventis Pharmaceuticals Inc.

The Commissioner is authorized to: (check all that apply)

 Charge fee(s) indicated below Credit any overpayments

 Charge any additional fee(s) during the pendency of this application

 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account

FEE CALCULATION

1. BASIC FILING FEE

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)
1001	770	2001	375
1002	340	2002	165
1003	530	2003	260
1004	770	2004	375
1005	160	2005	80
SUBTOTAL (1)		(\$ 770.00)	

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

	Extra Claims	Fee from below	Fee Paid
Total Claims	4	-20** = 0	x 18 = 0
Independent	1	- 3** = 0	x 86 = 0
Claims			
Multiple Dependent		0	= 0

Large Entity	Small Entity	Fee Description
Fee Code	Fee (\$)	Fee Code
1202	18	2202
		9
		Claims in excess of 20
1201	86	2201
		42
		Independent claims in excess of 3
1203	290	2203
		140
		Multiple dependent claim, if not paid
1204	86	2204
		42
		**Reissue independent claims over original patent
1205	18	2205
		9
		**Reissue claims in excess of 20 and over original patent
SUBTOTAL (2)		(\$ 0.00)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)
1051	130	2051	65
1052	50	2052	25
1053	130	1053	130
1812	2,520	1812	2,520
1804	920*	1804	920*
1805	1,840*	1805	1,840*
1251	110	2251	55
1252	420	2252	205
1253	950	2253	465
1254	1,480	2254	725
1255	2,010	2255	985
1401	330	2401	160
1402	330	2402	160
1403	290	2403	140
1451	1,510	1451	1,510
1452	110	2452	55
1453	1,330	2453	650
1501	1,330	2501	650
1502	480	2502	235
1503	640	2503	315
1460	130	1460	130
1807	50	1807	50
1806	180	1806	180
8021	40	8021	40
1809	770	2809	375
1810	770	2810	375
1801	770	2801	375
1802	900	1802	900
Other fee (specify)			

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

SUBMITTED BY

Complete (If applicable)

Name (Print/Type)	Balaram Gupta, Reg. No. 40,009	Registration No. (Attorney/Agent)	40,009	Telephone	(908) 231-3364
Signature	Balaram Gupta			Date	Jan. 20, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Aventis Pharmaceuticals Inc. template